title: Neutralizing antibodies respond to a bivalent dengue DNA vaccine or/and a recombinant bivalent antigen.
abstract: There is currently no effective vaccine to prevent dengue infection, despite the existence of multiple studies on potential methods of immunization. The aim of the present study was to explore the effect of DNA and/or recombinant protein on levels of neutralizing antibodies. For this purpose, envelope domain IIIs of dengue serotypes 1 and 2 (DEN-1/2)were spliced by a linker (Gly‑Gly‑Ser‑Gly‑Ser)3 and cloned into the prokaryotic expression plasmid pET30a (+) and eukaryotic vector pcDNA3.1 (+). The chimeric bivalent protein was expressed in Escherichia coli, and one‑step purification by high‑performance liquid chromatography was conducted. Protein expression levels of the DNA plasmid were tested in BHK‑21 cells by indirect immunofluorescent assay. In order to explore a more effective immunization strategy and to develop neutralizing antibodies against the two serotypes, mice were inoculated with recombinant bivalent protein, the DNA vaccine, or the two given simultaneously. Presence of the specific antibodies was tested by ELISA and the presence of the neutralizing antibodies was determined by plaque reduction neutralization test. Results of the analysis indicated that the use of a combination of DNA and protein induced significantly higher titers of neutralizing antibodies against either DEN‑1 or DEN‑2 (1:64.0 and 1:76.1, respectively) compared with the DNA (1:24.7 and 1:26.9, DEN‑1 and DEN‑2, respectively) or the recombinant protein (1:34.9 and 1:45.3 in DEN‑1 and DEN‑2, respectively). The present study demonstrated that the combination of recombinant protein and DNA as an immunization strategy may be an effective method for the development of a vaccine to prevent dengue virus infection.
authors.affiliation: Clinical Laboratory, Affiliated Quanzhou First Hospital of Fujian Medical University, Fuzhou, Fujian 350001, P.R. China.
authors.forename: Zhi-Shan
authors.initials: ZS
authors.lastname: Zhang
authors.affiliation: Fujian Center for Disease Control and Prevention, Fuzhou, Fujian 350001, P.R. China.
authors.forename: Yu-Wei
authors.initials: YW
authors.lastname: Weng
authors.affiliation: Fujian Center for Disease Control and Prevention, Fuzhou, Fujian 350001, P.R. China.
authors.forename: Hai-Long
authors.initials: HL
authors.lastname: Huang
authors.affiliation: Fujian Center for Disease Control and Prevention, Fuzhou, Fujian 350001, P.R. China.
authors.forename: Jian-Ming
authors.initials: JM
authors.lastname: Zhang
authors.affiliation: Fujian Center for Disease Control and Prevention, Fuzhou, Fujian 350001, P.R. China.
authors.forename: Yan-Sheng
authors.initials: YS
authors.lastname: Yan
mesh_terms: D000818:Animals; D057134:Antibodies, Neutralizing / Q000494:pharmacology*; D000914:Antibodies, Viral / Q000276:immunology; D003715:Dengue / Q000276:immunology*; D003716:Dengue Virus; D004797:Enzyme-Linked Immunosorbent Assay; D004926:Escherichia coli / Q000378:metabolism; D007114:Immunization; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests; D010957:Plasmids; D011994:Recombinant Proteins / Q000276:immunology*; D019444:Vaccines, DNA / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology*
chemical_list: D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D011994:Recombinant Proteins; D019444:Vaccines, DNA; D014765:Viral Vaccines